Burning Rock Biotech Ltd (BNR) Stock Forecast Oct. 30, 2026
Analysis updated on Oct. 30, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Burning Rock Biotech Ltd (BNR) stock forecast summary
This forecast was produced 3 trading days ago and has not been refreshed since; read it as historical, not as a current view.
Burning Rock Biotech Ltd is a small-cap company with a market capitalization of $117M. It ranks number 20 by market capitalization among the 26 Services-Medical Laboratories issuers in our coverage with a current forecast.
For BNR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -2.0%, measured on 357 forecast dates between 2022-08-12 and 2026-07-31 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 11.0%, measured on 400 forecast dates between 2022-08-12 and 2026-09-30. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.9%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
BNR price chart and AI forecast
How BNR ranks among 4891 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Burning Rock Biotech Ltd (BNR) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric. Statement values were filed in CNY and are shown converted to USD (flows at the trailing twelve-month average rate, balances at the balance-sheet date rate).
Valuation & Market
| Metric | BNR | Rank |
|---|---|---|
| Market Cap | $117M | 20/26 |
| P/B Ratio | 2.06x | 14/21 |
| Book Value/Share | $5.28 | – |
Financial Health
| Metric | BNR | Rank |
|---|---|---|
| D/E Ratio | 0.10x | 18/21 |
| Financial Leverage | 1.10x | 18/21 |
| Interest Coverage | -619.7x | 17/20 |
Dividend & Shareholder Information
| Metric | BNR | Rank |
|---|---|---|
| Shares Outstanding | 11M | – |
Balance Sheet Highlights (USD millions, converted from CNY)
| Total Liabilities | $6M | 9.1% of assets |
BNR quarterly financials and insider trading
Burning Rock Biotech Ltd (BNR) industry peers
Companies classified under the same SEC industry code as Burning Rock Biotech Ltd (Services-Medical Laboratories): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| BNR Burning Rock Biotech Ltd | $117M | |
| NTRA Natera, Inc. | $54.62B | |
| LH Labcorp Holdings Inc. | $28.84B | |
| DGX Quest Diagnostics Inc | $27.18B | |
| GH Guardant Health, Inc. | $23.48B | |
| CAI Caris Life Sciences, Inc. | $9.70B | |
| GRAL Grail, Inc. | $6.23B | |
| RDNT Radnet, Inc. | $5.78B | |
| BLLN Billiontoone, Inc. | $5.21B | |
| CDNA Caredx, Inc. | $4.52B | |
| VCYT Veracyte, Inc. | $3.94B | |
| CELC Celcuity Inc. | $3.38B | |
| FTRE Fortrea Holdings Inc. | $2.02B | |
| PSNL Personalis, Inc. | $1.68B | |
| FRNM Freenome, Inc. | $1.23B | |
| CSTL Castle Biosciences Inc | $1.07B | |
| LMRI Lumexa Imaging Holdings, Inc. | $1.07B | |
| FLGT Fulgent Genetics, Inc. | $533M | |
| BDSX Biodesix Inc | $222M | |
| XGN Exagen Inc. | $203M | |
| SERA Sera Prognostics, Inc. | $78M | |
| MDXH Mdxhealth Sa | $18M | |
| AMS American Shared Hospital Services | $8M | |
| ACON Aclarion, Inc. | $5M | |
| ADVB Advanced Biomed Inc. | $3M | |
| BGLC Bionexus Gene Lab Corp | $3M | |
| RNLXY Renalytix Plc | N/A |
Where BNR sits on the market map
Burning Rock Biotech Ltd (BNR) stock news
Loading...
Burning Rock Biotech Ltd (BNR) stock forecast FAQ
What is the Burning Rock Biotech Ltd (BNR) stock forecast?
This forecast was produced 3 trading days ago and has not been refreshed since; read it as historical, not as a current view.
How accurate are Burning Rock Biotech Ltd stock predictions?
For BNR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -2.0%, measured on 357 forecast dates between 2022-08-12 and 2026-07-31 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 11.0%, measured on 400 forecast dates between 2022-08-12 and 2026-09-30. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Burning Rock Biotech Ltd forecasts updated?
Burning Rock Biotech Ltd forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 30, 2026.
Which companies are Burning Rock Biotech Ltd's industry peers?
27 issuers in our coverage, BNR included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Labcorp Holdings Inc. (LH), Quest Diagnostics Inc (DGX), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Grail, Inc. (GRAL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.